IP Library Granted Patent US 8,394,620
Granted Patent B2
US 8,394,620 · App. 12/151,491 · Granted Mar 12, 2013

Two-component genome flavivirus and uses thereof

Inventors: Ilya V. Frolov (Galveston, TX); Alexandr V. Shustov (Astana, KZ)
Assignee: The Board of Regents of The University of Texas System
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,394,620
App. No.
12/151,491
Granted
Mar 12, 2013
Kind
B2
Abstract

The present invention discloses a two-component genome flavivirus and a method for propagating such virus. Since the genetic material of this flavivirus is distributed between two genomes, the flavivirus is deficient in replication, incapable of causing disease but capable of inducing an immune response. Nevertheless, the design of the replication deficient flavivirus discussed herein allows propagation of these flaviviruses at industrial level.

Claims (21)

1. A two-component genome flavivirus composition, comprising:

a first virus particle comprising a first viral genome encoding (i) an amino-terminal capsid fragment having more than the first 20 and at most the first 25 amino acids of the capsid protein, wherein the capsid fragment is not capable of nucleocapsid formation, (ii) a 5′ UTR, (iii) cis-acting promoter elements required for RNA replication, (iv) envelope proteins, and (v) a complete set of non-structural proteins of the flavivirus; and

a second virus particle comprising a complementing second viral genome encoding (i) a 5′ UTR, (ii) cis-acting promoter elements required for RNA replication, (iii) capsid protein, and (iv) a complete set of non-structural proteins of the flavivirus.

2. The composition of claim 1 , wherein said first virus particle or said second virus particle comprises a ubiquitine or a foot-and-mouth disease (FAMDV)-specific 2A protease fused to the sequence encoding the envelope proteins or the capsid protein.

3. The composition of claim 1 , wherein the first viral genome or the complementing second genome, or both further comprise a heterologous nucleic acid.

4. The composition of claim 1 , wherein the flavivirus is yellow fever virus, West Nile virus, dengue virus, tick-borne encephalitis virus, Saint Louis encephalitis virus, Japanese encephalitis virus, Murray Valley encephalitis virus, classical swine fever virus or hepatitis C virus.

5. A cell culture system comprising a cell infected with the composition of claim 1 .

6. The cell culture system of claim 5 , wherein the cell is Vero, BHK-21, C7/10 or other cells of vertebrate or mosquito origin.

7. A method of large-scale propagation of two-component genome flavivirus composition, comprising:

infecting a cell in culture with the composition of claim 1 wherein, both genomes replicate in the same cell; and

isolating viral particles produced by the infected cell.

8. The method of claim 7 , wherein said cell is infected with the two-component genome flavivirus at a multiplicity of infection of more than 1 infectious unit/cell.

9. The composition of claim 1 , further comprising an adjuvant, a pharmaceutically acceptable carrier or combinations thereof.

10. A method of inducing an immune response in a subject comprising:

administering the composition of claim 1 to the subject.

11. The method of claim 10 , wherein said administration is via intraperitoneal, intradermal, subcutaneous, intramuscular, oral or intranasal route.

12. The method of claim 10 , wherein said flavivirus is yellow fever virus, West Nile virus, dengue virus, tick-borne encephalitis virus, Saint Louis encephalitis virus, Japanese encephalitis virus, Murray Valley encephalitis virus, classical swine fever virus or hepatitis C virus.

13. The composition of claim 1 , wherein the amino terminal fragment of capsid protein is the first 25 amino acids of the capsid protein.

14. A two-component genome flavivirus composition, comprising:

a first flavivirus genome encoding (i) an amino-terminal capsid fragment having more than the first 20 and at most the first 25 amino acids of the capsid protein, wherein the capsid fragment is not capable of nucleocapsid formation, and (ii) an envelope protein; and

a second flavivirus genome (i) encoding a capsid protein capable of forming a nucleocapsid and (ii) having a deletion of the envelope genes.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jun 21, 2017
From: UNIVERSITY OF TEXAS MEDICAL BR GALVESTON
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 042922/0682 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2008
From: FROLOV, ILYA; SHUSTOV, ALEXANDR V.
To: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, THE
Reel/Frame 021787/0545 →
Continuity (2)
Provisional Application 60927993 · May 7, 2007
Related Publication 20090324623A1 · Dec 31, 2009